President Trump names Scott Gottlieb as the next FDA commissioner. What now?
President Trump has named Scott Gottlieb as the next FDA commissioner, resolving an issue that has huge implications for the biopharma industry and drug development.
Gottlieb’s nomination will be widely applauded by the biopharma industry, which will see the move as a commitment for continued reform without the kind of wholesale deregulation that would scuttle the agency’s gold standard for drug reviews.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.